Sionna's CF Pill Fails Phase 2 Trial, Stock Drops 90%
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sionna Therapeutics said its experimental pill SION-719 showed no benefit when added onto Vertex Pharmaceuticals' Trikafta in a Phase 2 trial for cystic fibrosis.
- Sionna will no longer advance SION-719 as an add-on therapy for CF patients after the mid-stage failure.
- The company hinted at potential layoffs, saying it will "take actions to preserve capital while evaluating next steps."
- Sionna's stock fell 90% in pre-market trading Monday morning following the trial results.
Why it matters: The failure eliminates a potential new add-on therapy for cystic fibrosis patients who rely on Vertex's Trikafta, and signals a near-existential crisis for Sionna — a 90% pre-market stock wipeout and hinted layoffs show the company is now scrambling to preserve capital after staking its lead program on this combination approach.
Ask SkimNews
